Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients
نویسندگان
چکیده
Möricke, A; Reiter, A; Zimmermann, M; Gadner, H; Stanulla, M; Dördelmann, N; Löning, L; Beier, R; Ludwig, W D; Ratei, R; Harbott, J; Boos, H; Mann, G; Niggli, F; Feldges, A; Henze, G; Welte, K; Beck, J D; Klingebiel, T; Niemeyer, C; Zintl, F; Bode, U; Urban, C; Wehinger, H; Niethammer, D; Riehm, H; Schrappe, M Möricke, A; Reiter, A; Zimmermann, M; Gadner, H; Stanulla, M; Dördelmann, N; Löning, L; Beier, R; Ludwig, W D; Ratei, R; Harbott, J; Boos, H; Mann, G; Niggli, F; Feldges, A; Henze, G; Welte, K; Beck, J D; Klingebiel, T; Niemeyer, C; Zintl, F; Bode, U; Urban, C; Wehinger, H; Niethammer, D; Riehm, H; Schrappe, M (2008). Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 111(9):4477-4489. Postprint available at: http://www.zora.uzh.ch
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke,1 Alfred Reiter,2 Martin Zimmermann,3 Helmut Gadner,4 Martin Stanulla,3 Michael Dördelmann,5 Lutz Löning,6 Rita Beier,7 Wolf-Dieter Ludwig,8 Richard Ratei,8 Jochen Harbott,2 Joachim Boos,9 Georg Mann,4 Felix Niggli,10 Andreas Feldges,11 Günter Henze,12 Karl Welte,3 Jörn-Dirk Beck,13 Thomas Klingebiel,14 Charlotte Niemeyer,15 Felix Zintl,16 Udo Bode,17 Christian Urban,18 Helmut Wehi...
متن کاملNUDT15 genetic variants and 6-mercaptopurine intolerance in pediatric acute lymphoblastic leukemia: an updated review
Acute lymphoblastic leukemia (ALL) accounts for nearly 30% of pediatric cancers. The maintenance treatment for ALL comprises daily oral 6-mercaptopurine (6-MP) and weekly methotrexate (MTX). 6-MP is a purine analog that can significantly improve the long-term survival of ALL patients. Despite more than 90% of 5-year survival of childhood ALL in developed countries, treatment interruption due to...
متن کاملBone Density in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL): A Literature Review
Introduction: Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children and the main form of childhood leukemia (75%). ALL different treatment options have a great impact on children weight and appetite. The improving prognosis for children with cancer refocuses attention to long-term outcomes with an emphasis on quality of life. More survival rate allows researchers to eval...
متن کاملEvaluation of Bone Mineral Density in Children with Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL)
Introduction: Acute lymphoblastic leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL) are the most common childhood and adolescence malignancy respectively.Due to the increasing survival of these children, today late side effects of treatments are important. Therapies such as corticosteroids, cytotoxic and radiotherapy effect on bone density and put the child at risk of osteoporosis and pathologi...
متن کاملTreatment of Ifosfamide -induced Encephalopathy with Methylene Blue in an Adolescent with Relapsed Acute Lymphoblastic Leukemia: a case report
Ifosfamide is one of the most important chemotherapeutic agents used for the treatment of numerous types of malignancies. Neurotoxicity is one of its life-threatening complications and is potentially fatal. In this paper we present a case of severe ifosfamide- induced encephalopathy in an adolescent with acute lymphoblastic leukemia in whom treatment with methylene blue led to complete improvem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010